TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial

MT Newswires Live05-18 12:12

TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.

Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.

Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636049845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 12:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636049845","market":"sg","top_or_hot":-1,"title":"TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial","media":"MT Newswires Live","content":"<html><body><p> TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.</p><p>Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.</p><p>Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-18 12:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.</p><p>Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.</p><p>Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636049845","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636049845","pubTimestamp":1779077575,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransThera Sciences   said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技"},"translate_title":"TransThera Sciences的Tinengotinib在试验中显示出抗肿瘤功效","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (Nanjing) (HKG:2617) said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636049845","isCrawlerRequest":true}